DK200200167A - Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines - Google Patents
Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines Download PDFInfo
- Publication number
- DK200200167A DK200200167A DK200200167A DKPA200200167A DK200200167A DK 200200167 A DK200200167 A DK 200200167A DK 200200167 A DK200200167 A DK 200200167A DK PA200200167 A DKPA200200167 A DK PA200200167A DK 200200167 A DK200200167 A DK 200200167A
- Authority
- DK
- Denmark
- Prior art keywords
- amino acid
- nucleic acid
- acid sequences
- vaccines
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Paper (AREA)
- Color Image Communication Systems (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
PATENTKRAV 1. Sammensætning omfattende i det mindste én aminosyresekvens valgt blandt gruppen bestående af SEQ ID nr. 2, 4, 6, 7, 8 og 10 og sekvenser, som er i det væsentlige homologe dermed, eller et hvilket som helst fragment deraf. 2. Sammensætning ifølge krav 1, hvori den i det mindste ene aminosyresekvens er en afkortet form af en aminosyresekvens valgt blandt gruppen bestående af SEQ ID nr. 2, 4, 6, 7, 8 og 10 og sekvenser, der er i det væsentlige homologe dermed. 3. Sammensætning ifølge krav 1, hvori den i det mindste ene aminosyresekvens er valgt blandt gruppen bestående af SEQ ID nr. 6, 7 og 8 og sekvenser, der er i det væsentlige homologe dermed. 4. Sammensætning ifølge et hvilket som helst af de foregående krav, hvori de i det væsentlige homologe sekvenser er mindst 70% homologe. 5. Sammensætning ifølge krav 4, hvori de i det væsentlige homologe sekvenser er mindst 80% homologe. 6. Sammensætning ifølge krav 5, hvori de i det væsentlige homologe sekvenser er mindst 90% homologe. 7. Sammensætning omfattende i det mindste én nukleinsyresekvens valgt blandt gruppen bestående af SEQ ID nr. 1, 3, 5 og 9 og sekvenser, der er i det væsentlige homologe dermed eller et hvilket som helst fragment deraf. 8. Sammensætning ifølge krav 7, hvori den I det mindste ene nukleinsyresekvens er en afkortet form af en hvilken som helst af SEQ ID nr. 1, 3, 5 eller 9 eller en sekvens, der er i det væsentlige homolog dermed. 9. Sammensætning ifølge krav 7, hvori den i det mindste ene nukleinsyresekvens er SEQ ID nr. 5 eller en i det væsentlige homolog sekvens. 10. Sammensætning omfattende i det mindste én nukleinsyresekvens, der koder for aminosyresekvensen af SEQ ID nr 2, 4, 6, 7, 8 eller 10 eller sekvenser, der er i det væsentlige homologe dermed. 11. Sammensætning ifølge et hvilket som helst af kravene 7 til 10, hvori de i det væsentlige homologe sekvenser er mindst 70% homologe. 12. Sammensætning ifølge krav 11, hvori de i det væsentlige homologe sekvenser er mindst 80% homologe. 13. Sammensætning ifølge krav 12, hvori de i det væsentlige homologe sekvenser er mindst 90% homologe. 14. Sammensætning ifølge et hvilket som helst af kravene 7 til 13, hvori nukleinsyresekvensen er inkorporeret i et plasmid. 15. Sammensætning ifølge et hvilket som helst af kravene 7 til 13, hvori nukleinsyresekvensen er inkorporeret i en ekspressionsvektor. 16. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 1 til 13 ved fremstilling af en vaccine og/eller et terapeutisk medikament til beskyttelse af fisk mod inficering med infektiøs lakseanæmi-virus. 17. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 1 til 13 ved fremstilling af et diagnostisk sæt til påvisning af tilstedeværelse i fisk af infektion med infektiøs lakseanæmi-virus. 18. Vaccine omfattende sammensætningen ifølge et hvilket som helst af kravene 1 til 13. 19. Diagnostisk testsæt omfattende sammensætningen ifølge et hvilket som helst af kravene 1 til 13. 20. Antistof, der er i stand til at påvise et peptid med aminosyresekvens ID nr. 10.
Figur 1: ISA2cd Nukleotidsekvens caagatggat aacctccgtg aatgcataaa ccgcaaaaga agactacCtg ccctaccaga 60 tgttccegaa acctcggatg cctttctaag tgatttgaga catctataca cgtgtgctgc 120 ttcctgtgat caacacaaaa ccactggaga cgaatcaaga tecaccaacc tggaattact 1B0 tgaccaagat gaagcactag gcgcccaaag agcttttgaa gccaaacatg gaataaaagg 240 aggttcttta ggagacgttc ttgaccatga actgaaaaag gtcattgaat ttacttttac 300 tccCggaagt tegcatattg ccgaacaaag aaaaagaaag acccaagcag acccaataac 360
Cgtgtgcgtt tcagaaggac ttaacgactt cagcgtatca cacggagcgc tagacatggg 420 acttgtggaa acaggggtga acgcagtaag agatttctgc acacaaaacg gaataccaat 480 gaagataaat caggtaggat ccacgagaac accaacaccg atcagcacat gcaaaatctc S40 tgaacaaata acacgacaga taaacagtac aattactgaa aggaaaacgg aaacagtact 600 ggcagcaatc gcaattaaac cagaactcaa actaactcag aaaggatgca gaccttgtaa 660 agaactagaa gatgaaaata ttctgtggat ggaccctcaa ttctgtgaaa ttgatgaaag 720 ttttccttac agaggagggc catacgggaa cttcctgcaa gaattgctgc ttacaaccaa 780 cgacgcagag accaacggga aagacagaga agaagtagta aagaagatac cggataacaa '840 ggcgttcaoc gttgaaagtg gtgaatgcat aataacactt ccagacaaaa tgacttgfctt 900 cggagaacag gagaagaaga gaccagcaac aatagacgaa gtgagaaccg caggagaaag 960 gtttgaacag agtgttaaac cgaaaaccca aagatatgga aggttatcag acaaatggat 1020 ggagcttgaa aagtttatct ttactgcaag caaaacagaa gtggatacct tcctttctgt 1080 agggaccgaa agacttgagt cggttggagt gcgtgtcgga gctttacaca gagcgaccac 1140 aaccaggata attagaccta tgattcaagg agggaaatgt tgggggatga tgttcaaaac 1200 aaagtccaaa atgggagaca cgaggaagga aggatactgt cacgcaatca ttttcggaaa 1260 aggggaagat aaatcaggac aaaacaagat gacaatgatg gggaaaacag tacattggca 1320 tctaagagta gttaagtcta aaggagactg gatggcgcaa caactctgtg caaacaaaag 1380 cagaacatgg gaacatgacc ctgagctagt aacagaagga gtgacagctc taatgacgcc 1440 tttttetcag aaaattgcoa ccattagtag atggagggea atgaggttag acagcatgtt 1500 tcatgtttct agtgcctggc atcattcacc cgcgtgtgaa gccgcaccgg caatgctgag 1560 aaagtttgtg gagatagtac atgccatcaa ccagaaaaga gattggggtg ttgtggggag 1620 tatggaggac atggtgaagg aagtggagga aataggggag cacttgcaga cggcatgtga 1680 ttttagagct eacaacatgt gcaaagcctt gattcagaaa attgcagcca gcacccaatg 1740 agtggttatt Cacttgtaaa ttgttgtgtg tttgacgata tgtatttgtc gacgcggccg 1800 cggtcgacgc ggccgcgaat t 1821
Figur 2: ISA2cd Aminosyresekvens 1 11 21 31 41 51 II! Ill 1 MDNLREC1NR KRRLLALPDV PETSDAFLSD LRHLYMCVAF CDQHKTTGDE SRFTWLELLD 60 SI QDEALGAQRA FEAKHGIKGG SLGDVLDHEL KKVIEFTFTS GSLYIAEQRK RKTQADSIIV 120 121 CVSEGLNDFS VSHGVLDMGL VETGVNAVRD FCTQH3IPMK INQVGSTR.TP TPISTCKISE 180 181 QITRQINSTI TERKMETVLA AIAIKPELKL TQKGCRPCKE LEDENILWMD PQFCEIDESF 240 241 PYRGGPYGNF LQELLLTTND VETNGKDREE WKKILDNKA FTVESGECI1 TLPDKMTCFG 300 301 EQEKKRPATI DEVRTAGERF EQSVKPKTQR YGRLSDKWME LEKFIFTASK TEVDTFLSVG 360 361 TERLESVGVC VGALHRATTT RIIRPHIQGG KCWGMMFKTK SKMGDTRKEG YCHAIIFGKG 420 4 21 EDKSGQNKMT MMGKTVHWHL RWKSKGDWM AQQLCANKSR IWEHDPELVT EGVTVLMTPF 4B0 481 SQKIATISRW RAMRLDSMFH VSSAWHHSPA CEAASAMLRK FVEIVHAINQ KRDWGWGSM 54 0
541 EDMVKEVEEI GEHLQTACDF RVYWMCKAUI QKIAVSTC
Molekylvægt: 65336.10 Teoretisk pi: 6.94
Figur 3: ISAImta Nukleotidsekvens gcaaagatyg ctcaaacccc aaaaacaata cagaaaacgt ataagagatg gccgacaaag go gtatgactta ttctcttgat gtcagagaca acaccttggt tgcaagaaga tctaccgcta 120 ctaaaagtgg cactaagatc ccctacagag aggatcgagg aacatcactb ctccaaaagg ieo cactcgccgg gacagaagat gaattctggg tggagttaga tcaagatgtc Cacgttgaca 240 aaaagattag aaaacccctg gaagaagaga aaatgaagga catgagcaca agagtgtctg 300 gagcagtggc agcagcaatt gaaagaccag ctgaatttga caatttctca aaagaagcag 360 cagccaacat tgaaatggct ggtgtagatg atgaagaagc tggaggaagt ggtctggcag 420 acaacagaag gaagaacaaa ggggcctcaa acatggccta caatctgtct ctattcatag 480 ggatggtgtt tcctgctctc actactttct tcagcgctac cctaccagaa ggtgaaatga 540 gcatccggca aaatggacaa gcaatcatca gaaCtcCggc actggcagat gaagacggaa 600 agagacaaac aagaacagga ggacagaggg tggacatggc tgatgtaacc aagctgaacg 660 taglcacggc taacgggaaa gtcaagcaag ttgaagcaaa cttgaacgat ctcaaagcag 720 cactcaggca gagtagacct aaaagatcgg actacagaaa agggcaaggt tccaaggcta 780 cagaatcaag catctccaac caatgtatgg cactgattat gaaatctgtg ctgtcagcag 840 aceaactttt tgctccggga gtgaagacga tgaggacgaa cggtttcaat gegecgtaca 900. caacactggc agaaggggca aacattccga gcaagcacct aagacacatg aggaaccgcg 960 gaggagtagc tctggacctg atgggaatga agaggatcaa aaactcacct gaaggagcca 1020 agtctaagac cttCtccatc atccagaaga aagcaagagg aagatgtcgc acagaggagc 1080 aacgcctcct gaccagcgca cbgaaaacca gcgacggtga aaacaagtcc cagagaatca 1140 cggacactct atgcacaagc ttcctgattg accctccaag aactaccaaa Cgcttcattc 1200 cacctatttc cagccccatg atgtacatcc aagaaggcaa ctctgtaccg gcaacggatt 1260 tcatgaaaaa cggagaggac gcctgcaaga tccgcagaga agccaaactg aaagtggggg 1320 taaacagtac gctcacaacg tcagtagcta gaacacgcgt tgcagtgtca atggttgcaa 1380 cagcttettg ttctgcagat atcatcgaga atgcagtgcc tggttccgaa aggtacagac 1440 ccaacaccaa ggctaacaca accaaaccaa aaaaggaccc cactcacaca att^caaggac 1500 ttagatcgtc taacgcgagg tatgaagcaa gacctgaaac atcacaaagc aacacagaca 1560 gaagttggca agtgaacgtg actgacagct tcggaggact tgctgtgttc aaccaagggg 1620 caaccagaga aatgctagga gacggaacat cagagacaac tagtgtgaac gtcagagccc 1680 tggtgaagag aattctgaaa ccagcttcag agaggagtgc aagagctgta aagacattta 1740 tggtgggaga acaagggaaa tcagctatCg ttatctctgg tgtgggactg ttctctattg 1800 actttgaagg ggtagaggaa gcggaaagga taactgacat gacacctgaa attgagcttg i860 acgaggacga cgaggaagag gaagacattg acatttagag cgacaattat gtaactttct 1920 aattacccta tattgtttga atatataatg aaactaCCgt gtgttaaagg tcgtgggbtt 1980 gaccactaaa cttaaaccga aacggcaccg acgacact 2018
Figur 4: ISAImta Aminosyresekvens 1 11 21 31 41 51
III III 1 MADKGMTYSF DVRDNTLWR RSTATKSGIK ISYREDRGTS LLQKAFAGTE DEFWVELDQD SO 61 VYVDKKIRKF LEEEKMKDMS TRVSGAVAAA IERSVEFDNF SKEAAANIEM AGVDDEEAGG 120 121 SGLVDNRRKN KGVSNMAYNL SLFIGMVFPA LTTFFSAILS EGEMSIWQNG OAI1RILAIA 180 181 DEDGKRQTRT GGQRVDMADV TKLNWTANG KVKQVEVNLN DLKAAFRQSR PKRSDYRKGQ 24 0 241 GSKATESSIS NQCMALXMKS VLSADQLFAP GVKMMRTNGF NASYTTIAEG ANIPSKYUXH 300 301 MRNCGGVALD LMGMKRIKNS PEGAKSKXFS IIQKKVRGRC RTEEQRLLTS ALKISDGENK 360 361 FQRIMDTLCT SFLIDPPRTT KCFIPPrSSL MMYIQEGHSV IAMDFMKNGE DACKXCREAK 4 20 421 I.KVGVNSTFT MSVARTCVAV SMVATAFCSA DIIENAVPGS ERYRSNIKAN TTKPKKDSTY 4 80 481 TIQGLRZiSNV RYEARPETSQ SNTDRSWQVN VTDSFGGIAV FNQGAIREML GDGTSETTSV 540 541 NVRALVKRIL KSASERSARA VKTFMVGEQG KSAXVISGVG LFSIDFEGVE EAERITDMTP 600
601 EIEFDEDDEE EEDIDI
Molekylvægt: 68050.47 Teoretisk pi: 8.20
Figur 5: ISA3mx Nukleotidsekvens atgtctggat ttaacctcga ggtaatggtg ccggaacaag gaggaaaagt ggtcttcagc go cttactgaaa cggggtcatg tgtctcgttt tacggagacg acgaaccagg tgaagggtcc 120 cgcgaacttg cctctgaaaa catggatttt ccaagtcgtc ctctggggaa tggagatgac 180 ttctgtctgt cgceggcgct aagcacaatg agatggtctg ggacgaccaa gagaaacaac 240 ttcatggaca gattcattgg aagttttgct cactgtacac cagtgatgat ctggtcgtat 300 ggaaaettgt ccaagaaaag ccatcacaaa acggttcgcc acacttgccc agacgagtac 360 aagttcagtg acaaggacga gatgcaggga tactatgagg gatgtctaga ggcttctact 420 gacatttccc Ctgatgaact tgctactgtt gttacaggtg gcttctttcc tgtcggactc 480 aaaggttcct ggggaggatg ' gtacctcaag tacgtcaggt aegctggacc ccttgcggga 540 tcaagtggat tcattgtcaa tcaacgattc tacgacagag cccaaaacaa gactggatcc 600 agggttgtat ccacggttga aatggacgga gacggcctat cgttcatcta cgagaagccc 660 agcgtctacc atagtga'jgg gtgcaccggg tcagcagcga ggttccggaa acgggaccac 720 aatgagagag ctggagttga gcttagggct ggacttcact tcagaatgtg attggtcgaa 780 aacttgttat gcaaacaaga attttgcgtt tctgtcagaa aaagaaattg ctgtaaacat 840 ggaagttgaa aaattcattt gtaatgagaa etaaagatgt ccttgtgttc aaactttaac 900 taatgacaat atatgaaata tgtcgtacat ggtgctgatg ataattttca aaacgaaaag 960 gagaaetttt actaaaataa aaaaaaaata aaaaaaaaaa aaaagaaaaa aaaaaaaaaa 1020 aaaaaaagtc gacaccgata cgcgcggtca 1050
Figur 6a: Forudsagt aminosyresekvens af ikke-splejset (M1) produkt af ISA3mx MSGFNLEVMVPEQGGKWFSLTETGSCVSFYGDDEPGEGSCELASENMDFPSCPLGNGDD 60 FCLSLALSTMRWSGMTKRNNFMDRFIGSFVHCTPVMIWSYGNLSKKSHHKMVCHTCPDEY 120 KFSDKDEMQGYYEGCLEASTDIFLDELATVVTGGFFPVGLKGSWGGWYLKYVRYAGLAG 180 SSGFIVNQRFYDRAQNKTGSRWSMVEMDGDGLSFIYEKPSVYHSDGCTGSAARFWKRDH 240 NERAGVELRAGLHFRM 256
Molekylvægt: 28.498 Teoretisk pi: 5.38
Figur 6b: Forudsagt aminosyresekvens af splejset (M2) produkt af ISA3mx MSGFNLEVMVPEQGGKWFSLTETGSCVSFYGDDEPGGFFPVGLKGSWGGSYLKYVRYAG 60 PLAGSSGFIVNQRFYDRAQNKTGSRWSMVEMDGDGLSFIYEKPSVYHSDGCTGSAARFW 120 KRDHNERAGVELRAGLHFRM 140
Molekylvægt: 15.357 Teoretisk pi: 6.82
Figur 6c: Forudsagt aminosyresekvens af splejset (M3) produkt af ISA3mx MNLLLLLQVASFLSDSKVPGEDGTSSTSGMLDLLRDQVDSLSINDSTTEPKTRLDPGLYP 60 WLKWTETAYRSSTRSLASTIVMGALGQQRGSGNGITMRELELSLGLDFTSECDWLKTCYV 120 NKNFVFLSEKEIAVNMEVEKFICNEN 147
Molekylvægt: 14.888 Teoretisk pi: 4.65
Figur 7: ISA4ha Nukleotidsekvens
cagtcgtcta tgtcttagaa accatcctga caccacctgg ataggtgact cccgaagcga GO tcaatcaagg gtgaaccaac agtctcttga tctggtcaca aacttcaagg gaattctaca 120 agccaagaac gggaacggtc tcatgaagca gatgagcgga aggcccccaa gtgattggta 180 ccaacctact acaaagtata ggattctata cattggtaca aacgactgca ctgagggccc 240 taacgacgtg atcataccga cgtcaatgac actagacaat gtggcaaggg acctgtacct 300 gggagcacgt cgaggagatg taagagcgac accaaccccc gtgggagcag ccgagctcgg 360 aocgactggg agaacagatg ccttaacagg atttcctgca aaggtgctga ctttcaacaa 120 ccctactatt gtagtagttg gactaaatgg aatgtcagga atctacaagg tctgcattgc 180 tgcctcttct ggaaacgcag gcggagccaa cttggtgaac ggatgcggat acttcagcgc 540
tcctctgaga ttcgacaact tcaaaggaca gatctacgtg tcagacacct ttgaagtcag SOO aggaacaaag aacaaatgtg tcatacttag atcttctagc aatgctcctt tgtgtacaca 560 catcaaaaga aacattgagt tggatgagta cgttgacaca ccaaacactg ggggcgtata 720
Cccttctgat gggtttgatt ctcttcacgg ctctgcttcg attagaactt ttttaacaga 780 ggcactgaca tgtccaggtg tagattggga cagaattgat gcagcttcat gcgagtatga Θ40 cagttgtcct aaacctgtga aagaatctga ccaaacaggg cccggaaaca cagatactca .. 900 aataatgaga gagctagaag cacaaaagga gatgattggt aaacttggca gaaacattac 960 agacgtaaac aacagagtag atgctattcc accacagctt agcaacatct tcatctctat 1020 gggagtggca ggt 1033
Figur 8: ISA4ha Aminosyresekvens 1 11 21 31 41 51
III III 1 SRLCLRNHPD TTWIGDSRSD QSRVNOQSLD LV7MFKGIU) AKNGNGLMKQ MSGRFPSDKY 60 61 QPTTKYRILY IGTNDCTEGP NDVIIPTSMT LDNVARDLYL GACEGDVRVT PTFVGAAELG 120 121 LXGRTDALTG FSVKVLTFNN PTIVWGLNG MSCIYKVCXA ASSGMVGGVN LWGCGYFSA 180 181 PLRFDNFKGQ IYVSDTFEVR GTKNKCVXLR SSSNAPLCTH IRKKIELDEY VDTPNTGGVY 240 241 PSDGFDSLHG SASIRTFLTE ALTCPGVDWD RIDAASCEYD SCPXLVKEFD QTCLGUTDTQ 3 00
301 IMRELEAQKE MIGKLGRNIT DVNNRVDAIP PQLSNIFISM GVAG
Molekylvægt: 37.437
Teoretisk pi: 5.38
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9918588.6A GB9918588D0 (en) | 1999-08-07 | 1999-08-07 | Sequence |
| GB0005848A GB0005848D0 (en) | 2000-03-11 | 2000-03-11 | Sequence |
| GB0006674A GB0006674D0 (en) | 2000-03-21 | 2000-03-21 | Sequence |
| PCT/GB2000/002976 WO2001010469A2 (en) | 1999-08-07 | 2000-08-07 | Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK200200167A true DK200200167A (da) | 2002-04-02 |
| DK177298B1 DK177298B1 (en) | 2012-10-15 |
Family
ID=27255591
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00949769.4T DK1200132T4 (da) | 1999-08-07 | 2000-08-07 | Nucleinsyre-og aminosyresekvenser af infektiøs lakseanæmivirus og deres anvendelse som vacciner |
| DKPA200200167A DK177298B1 (en) | 1999-08-07 | 2002-02-05 | Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00949769.4T DK1200132T4 (da) | 1999-08-07 | 2000-08-07 | Nucleinsyre-og aminosyresekvenser af infektiøs lakseanæmivirus og deres anvendelse som vacciner |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US6919083B1 (da) |
| EP (2) | EP1200132B2 (da) |
| AT (1) | ATE332712T1 (da) |
| AU (1) | AU6304100A (da) |
| CA (1) | CA2378437C (da) |
| CY (1) | CY1106175T1 (da) |
| DE (1) | DE60029327T2 (da) |
| DK (2) | DK1200132T4 (da) |
| ES (1) | ES2267553T3 (da) |
| NO (1) | NO328740B1 (da) |
| PT (1) | PT1200132E (da) |
| WO (1) | WO2001010469A2 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001010469A2 (en) | 1999-08-07 | 2001-02-15 | Novartis Ag | Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
| EP1094069B2 (en) * | 1999-10-18 | 2008-04-23 | Intervet International BV | DNA encoding structural protein-1 of infectious salmon anaemia virus and uses thereof |
| EP1263781B1 (en) * | 2000-03-08 | 2006-11-22 | The University Court of The University of Aberdeen | Viral antigen and vaccine against isav (infectious salmon anaemia virus) |
| AU2001295584A1 (en) * | 2000-09-28 | 2002-04-08 | Akzo Nobel N.V. | Matrix proteins m1 and m2 of infections salmon anaemia virus |
| GB0216414D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| EP2113511A4 (en) | 2006-12-22 | 2010-09-15 | Soluciones Biotecnologicas Inn | DNA VACCINES FOR FISH |
| US9395356B2 (en) | 2009-10-02 | 2016-07-19 | The National Veterinary Institute | Piscine reovirus immunogenic compositions |
| US20130243803A1 (en) * | 2012-03-09 | 2013-09-19 | Samuel Bogoch | Therapies, vaccines, and predictive methods for infectious salmon anemia virus |
| WO2021123099A1 (en) * | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Reassorted isa virus |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO311648B1 (no) | 1999-05-31 | 2001-12-27 | Genomar Asa | DNA-sekvenser som kan benyttes til vaksine, forebyggende helsearbeid på fisk og akvatiske organismer og ellers innenbiomedisin, vektor, vaksine mot ILA-virus samt diagnostisk sett |
| WO2001010469A2 (en) | 1999-08-07 | 2001-02-15 | Novartis Ag | Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
| EP1094069B2 (en) | 1999-10-18 | 2008-04-23 | Intervet International BV | DNA encoding structural protein-1 of infectious salmon anaemia virus and uses thereof |
| WO2001049712A2 (en) | 2000-01-07 | 2001-07-12 | Akzo Nobel N.V. | Vaccine against isav (infectious salmon anaemia virus) |
| EP1263781B1 (en) | 2000-03-08 | 2006-11-22 | The University Court of The University of Aberdeen | Viral antigen and vaccine against isav (infectious salmon anaemia virus) |
| AU2001295584A1 (en) | 2000-09-28 | 2002-04-08 | Akzo Nobel N.V. | Matrix proteins m1 and m2 of infections salmon anaemia virus |
-
2000
- 2000-08-07 WO PCT/GB2000/002976 patent/WO2001010469A2/en not_active Ceased
- 2000-08-07 DK DK00949769.4T patent/DK1200132T4/da active
- 2000-08-07 AU AU63041/00A patent/AU6304100A/en not_active Abandoned
- 2000-08-07 PT PT00949769T patent/PT1200132E/pt unknown
- 2000-08-07 AT AT00949769T patent/ATE332712T1/de not_active IP Right Cessation
- 2000-08-07 CA CA2378437A patent/CA2378437C/en not_active Expired - Lifetime
- 2000-08-07 EP EP00949769A patent/EP1200132B2/en not_active Expired - Lifetime
- 2000-08-07 DE DE60029327T patent/DE60029327T2/de not_active Expired - Lifetime
- 2000-08-07 EP EP05018866A patent/EP1637614A3/en not_active Withdrawn
- 2000-08-07 US US10/049,086 patent/US6919083B1/en not_active Expired - Lifetime
- 2000-08-07 ES ES00949769T patent/ES2267553T3/es not_active Expired - Lifetime
-
2002
- 2002-02-05 NO NO20020573A patent/NO328740B1/no not_active IP Right Cessation
- 2002-02-05 DK DKPA200200167A patent/DK177298B1/da not_active IP Right Cessation
-
2004
- 2004-04-02 US US10/734,782 patent/US7128917B2/en not_active Expired - Lifetime
-
2005
- 2005-03-18 US US11/083,801 patent/US7199108B2/en not_active Expired - Lifetime
- 2005-03-18 US US11/083,800 patent/US7201910B2/en not_active Expired - Lifetime
-
2006
- 2006-09-22 US US11/525,695 patent/US20070041988A1/en not_active Abandoned
- 2006-09-28 CY CY20061101410T patent/CY1106175T1/el unknown
-
2009
- 2009-11-24 US US12/624,918 patent/US7998484B2/en not_active Expired - Fee Related
-
2011
- 2011-08-12 US US13/208,709 patent/US20120071630A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60029327T2 (de) | 2007-07-05 |
| US20070041988A1 (en) | 2007-02-22 |
| US7998484B2 (en) | 2011-08-16 |
| PT1200132E (pt) | 2006-11-30 |
| US20100136038A1 (en) | 2010-06-03 |
| DE60029327D1 (de) | 2006-08-24 |
| DK1200132T3 (da) | 2006-10-23 |
| DK1200132T4 (da) | 2010-04-19 |
| WO2001010469A2 (en) | 2001-02-15 |
| US7201910B2 (en) | 2007-04-10 |
| NO20020573D0 (no) | 2002-02-05 |
| CA2378437C (en) | 2014-01-21 |
| NO20020573L (no) | 2002-04-05 |
| DK177298B1 (en) | 2012-10-15 |
| NO328740B1 (no) | 2010-05-03 |
| WO2001010469A3 (en) | 2001-09-07 |
| US6919083B1 (en) | 2005-07-19 |
| EP1637614A2 (en) | 2006-03-22 |
| ES2267553T3 (es) | 2007-03-16 |
| US20040146860A1 (en) | 2004-07-29 |
| US20120071630A1 (en) | 2012-03-22 |
| EP1200132A2 (en) | 2002-05-02 |
| ATE332712T1 (de) | 2006-08-15 |
| EP1200132B2 (en) | 2010-02-17 |
| US7128917B2 (en) | 2006-10-31 |
| CY1106175T1 (el) | 2011-06-08 |
| AU6304100A (en) | 2001-03-05 |
| CA2378437A1 (en) | 2001-02-15 |
| US7199108B2 (en) | 2007-04-03 |
| EP1200132B1 (en) | 2006-07-12 |
| US20050164176A1 (en) | 2005-07-28 |
| EP1637614A3 (en) | 2006-11-29 |
| US20050261227A1 (en) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Levi et al. | Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection | |
| Robinson et al. | DNA immunization for influenza virus: studies using hemagglutinin-and nucleoprotein-expressing DNAs | |
| Kast et al. | Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. | |
| EP1651264B1 (en) | Subunit vaccine against respiratory syncytial virus infection | |
| Johansson et al. | Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition | |
| Deliyannis et al. | Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus | |
| AU2010200048A1 (en) | Compositions of influenza viral proteins and methods of use thereof | |
| DK200200167A (da) | Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines | |
| Arunkumar et al. | Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice | |
| US20090162400A1 (en) | Compositions of influenza viral proteins and methods of use thereof | |
| Loke et al. | Improved protection from velogenic Newcastle disease virus challenge following multiple immunizations with plasmid DNA encoding for F and HN genes | |
| US20120014972A1 (en) | Influenza virus compositions and methods for universal vaccines | |
| CA2764903A1 (en) | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens | |
| Schrijver et al. | Comparison of DNA application methods to reduce BRSV shedding in cattle | |
| Zhao et al. | Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant | |
| CN115916254A (zh) | 疫苗、佐剂和产生免疫应答的方法 | |
| US20230398201A1 (en) | Gene shuffled lyssavirus vaccine | |
| Soleimani et al. | Improvement influenza HA2 DNA vaccine cellular and humoral immune responses with Mx bio adjuvant | |
| Oveissi et al. | DNA vaccine encoding avian influenza virus H5 and Esat-6 of Mycobacterium tuberculosis improved antibody responses against AIV in chickens | |
| Singh et al. | Immunological response of the respiratory tract in the SARS-CoV-2 infection | |
| Tarpey et al. | Cloning, expression and immunogenicity of the avian pneumovirus (Colorado isolate) F protein | |
| WO2002062381A1 (en) | Baculovirus vector vaccine | |
| Zhang et al. | Immunogenicity of a recombinant Sendai virus expressing the capsid precursor polypeptide of foot-and-mouth disease virus | |
| Sharma et al. | Immune responses of lambs to the fusion (F) glycoprotein of bovine respiratory syncytial virus expressed on insect cells infected with a recombinant baculovirus | |
| Attaran et al. | Immunogenicity and protective efficacy of recombinant M2e. Hsp70c (Hsp70359–610) fusion protein against influenza virus infection in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |
Expiry date: 20200807 |